Vor Biopharma (VOR) Share-based Compensation (2020 - 2026)

Vor Biopharma (VOR) has reported Share-based Compensation for 7 consecutive years, with $8.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Share-based Compensation rose 358.87% year-over-year to $8.9 million; the TTM figure through Mar 2026 stood at $34.6 million (up 297.47% YoY), while the FY2025 annual figure was $113.4 million, up 1051.62% from the prior year.
• Share-based Compensation declined to $8.9 million in Q1 2026 per VOR's latest filing, from $15.8 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $16.6 million in Q4 2022 and bottomed at -$10.3 million in Q4 2023.
• Historically, Share-based Compensation has averaged $3.8 million across 5 years, with a median of $2.3 million in 2024.
• Annual changes were most pronounced in 2022 — Share-based Compensation soared 1276.56% — and 2023, when it slumped 162.08%.
• Vor Biopharma's Share-based Compensation stood at $16.6 million in 2022, then plunged by 162.08% to -$10.3 million in 2023, then jumped by 116.62% to $1.7 million in 2024, then soared by 826.45% to $15.8 million in 2025, then sank by 43.98% to $8.9 million in 2026.
• Business Quant data shows VOR's Share-based Compensation at $8.9 million in Q1 2026, $15.8 million in Q4 2025, and $8.0 million in Q3 2025.